Introduction: Duodenal adenomas have potential for malignant transformation. Hence, surgical or endoscopic removal is recommended. Due to the high morbidity associated with surgical resection, EMR is being increasingly used, but there are no guidelines for endoscopic management of duodenal adenomas. There is also a lack of long-term follow-up data after endoscopic removal. Reported complication and recurrence rates from western data range between 25-33% and 24-37%. This is in comparison to Asian data showing 0-13% complications and 0-13% recurrence rate. The purpose of our study was to evaluate the safety and efficacy of EMR for non-ampullary duodenal adenomas. Methods: Retrospective IRB-approved study of patients with biopsy-proven duodenal adenomas from 2006 and 2013. Ampullary and periampullary adenomas were excluded. Patients had their first follow-up endoscopy at 3-6 months and then yearly. The main outcome measures were complete resection, complications, and incidence of residual and recurrent adenomas. Results: Twenty-nine patients underwent EMR using submucosal lift injection and hot snare technique. The mean age of patients was 65.1 years, and 51.7% were females. Majority of polyps were sessile (93%) and in the second duodenum (79.3%), with a mean size of 23.1 mm (range 10-50 mm). Sixty-nine percent of adenomas were resected in piecemeal fashion while only 9 (31%) were resected en-bloc. Thermal therapy was used in 55.2% adenomas for tissue destruction at the margins, and clips were placed in 82.8% of the patients. Three patients (10.3%) developed bleeding requiring hospitalization and endoscopic hemostasis. No perforations were noted, and none of the patients required any surgical intervention. Histology showed 82.8% of patients had tubular adenomas, while 5 patients (17.2%) had villous features. Follow-up data was available for 19 patients (65.5%), and the mean follow-up duration was 23.2 months. Three patients (15.8%) had residual adenoma at the first follow-up endoscopy, while 4 patients (21%) had recurrent adenomas (diagnosed if at least one priorendoscopic exam with biopsies negative for residual adenoma) at the site of resection after a mean follow-up period of 36.5 months (range 8-60 months). Conclusion: EMR is a safe and effective treatment for large duodenal adenomas. The adenoma size in our study was larger compared to previously published data, likely due to the referral-based nature of our practice. Despite removal of larger sized adenomas, our data showed good long-term outcomes and a low rate of complications. The recurrence rate in our study is comparable to previously published data, and recurrences can be successfully managed endoscopically. These patients require close follow-up with surveillance endoscopies, and surveillance guidelines are needed.
Read full abstract